Skip to main content
Clinical Trials/NCT06315725
NCT06315725
Recruiting
Not Applicable

A Randomized Cross-Over Study to Investigate the Effect of the Non-Nutritive Sweetener Sucralose on Glucose Metabolism in Patients with Type 1 Diabetes

McGill University Health Centre/Research Institute of the McGill University Health Centre1 site in 1 country25 target enrollmentNovember 12, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Type 1 Diabetes (T1D)
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Enrollment
25
Locations
1
Primary Endpoint
Effectiveness and optimal time course of sweet test blockade on sweet taste perception in healthy individuals
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The goal of this randomized crossover study is to test the prediction that consuming carbohydrates will affect insulin release differently depending on whether Non-Nutritive Sweeteners (NNSs) are consumed simultaneously. We aim to determine whether the predicted effects are associated with oral or post-oral sweet taste receptor signaling,. Our study will focus on patients diagnosed with type 1 diabetes (T1D) who are using an artificial pancreas (AP) system, as it allows us to monitor glucose and insulin levels over time.

Participants will drink four different flavored beverages, some with sweet taste blockade and some without, in a counter-balanced order. They will then rate the sweetness of each beverage, and we will collect data from their AP system to monitor insulin and glucose level.

To achieve this, we will conduct a pilot study to assess the effectiveness and best timing of sweet taste blockade in healthy individuals. Insights gained from the pilot study will inform the main study.

Sucralose will be used as the NNS, maltodextrin as the carbohydrate, and Gymnema Sylvestre (GS) as the sweet taste receptor blocker.

Registry
clinicaltrials.gov
Start Date
November 12, 2024
End Date
December 1, 2027
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Responsible Party
Principal Investigator
Principal Investigator

Dana Small

Professor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Eligibility Criteria

Inclusion Criteria

  • Participants with a diagnosis of T1D
  • HbA1C ≤ 8 %
  • Insulin pump therapy
  • Adults of any gender or biological sex aged 18-45 years old,
  • Body Mass Index (BMI) between 18.5-29.9 kg/m,
  • Non-smokers,
  • English or French speaker. ●. Who can consume chicken and fish

Exclusion Criteria

  • A major medical diagnosis that could potentially influence metabolic dysfunction
  • A major medical diagnosis other than T1D,
  • Alcohol or substance use disorder,
  • Eating disorder or history of malabsorptive syndrome,
  • Inflammatory bowel disease,
  • Self-reported impairment in taste or smell,
  • A known taste or smell dysfunction (e.g., anosmia),
  • Active pregnancy and/or lactation,
  • Food allergies or intolerances,
  • Dislike of the test beverages,

Outcomes

Primary Outcomes

Effectiveness and optimal time course of sweet test blockade on sweet taste perception in healthy individuals

Time Frame: from enrollment to the end of treatment at 4 weeks

our aim is to test whether the impact of consuming NNS with carbohydrates on glucose metabolism is related to oral or post-oral sweet taste receptor signaling.

Mean plasma glucose, basal and bolus insulin changes in individuals with T1D on AP following beverage consumption.

Time Frame: From enrollment to the end of treatment at 4 weeks

Consuming NNS alongside carbohydrates affects glucose metabolism differently compared to carbohydrates alone in participants with type 1 diabetes (T1D) using an artificial pancreas (AP) system for exogenous insulin production

Secondary Outcomes

  • Resting Energy Expenditure (REE) and nutrient partitioning changes in individuals with T1D on AP following beverage consumptionT1D on AP following beverage consumption(from enrollment to the end of treatment at 4 weeks)

Study Sites (1)

Loading locations...

Similar Trials